Study of Serum Beta Catenin Levels in Patients of Breast Carcinoma in North Indian population

##plugins.themes.academic_pro.article.sidebar##

Published Feb 1, 2021
Download
PDF
Statistic

Downloads

Download data is not yet available.
Vol. 4 No. 01 (2021): International Journal of Medical Science in Clinical Research and Review

##plugins.themes.academic_pro.article.main##

Isha Malik
Professor

Abstract

Background: Breast cancer is a malignant proliferation of epithelial lining of ducts or lobules of breast and occurs due to hyper- estrogenic states. It appears that estrogen and progesterone act through proto-oncogenes and growth factors to affect breast cancer etiology. Beta catenin is a proto-oncogene and the mutation of this gene is found in a variety of cancers including primary hepatocellular carcinoma, colorectal cancer and breast cancer. It may be one of the marker in breast cancer as it is having impact on cyclic D pathway but the precise role is not known. Aim and Objectives: To estimate the serum levels of beta catenin in patients of carcinoma breast and to compare with age matched healthy controls. Methodology: The present study was conducted in the department of Biochemistry in collaboration with department of  Radiotherapy and Surgery in PGIMS Rohtak. Twenty five patients with histopathological proven carcinoma breast were taken for the study and same number of  age matched subjects served as controls. Serum beta catenin was assessed by enzyme linked immunosorbent assay ( ELISA) along with routine biochemistry of all the subjects. Results: The  beta catenin levels were found to be  increased in  the cases as compared to controls. The  mean value was 43.32±9.39 pg/mL in cases and 19.6±4.17pg/mL in control subjects  and p value was significant. Conclusion: Beta catenin may play a role in the pathogenesis of breast cancer and can be used as a prognostic marker.

##plugins.themes.academic_pro.article.details##

How to Cite
Malik, I. (2021). Study of Serum Beta Catenin Levels in Patients of Breast Carcinoma in North Indian population. International Journal of Medical Science in Clinical Research and Review, 4(01), Page: 19–24. Retrieved from https://ijmscrr.in/index.php/ijmscrr/article/view/129

References

    1. Perou CM, Sorlie T, Eisen MB, Matt VR, Jeffrey SS, Rees CA, et al. Molecular portrait of human breast tumours. Nature 2000;406:747-52.
    2. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA2008; 299 (2): 194–201.
    3. Smith CJ, Ryckman KK. Epigenetic and developmental influences on the risk of obesity, diabetes, and metabolic syndrome. Diabetes Metab Syndr Obes. 2015;8:295–302.
    4. Erdogan IZ, et al. Preoperative lymphedema-related risk factors in early-stage breast cancer. Lymphat Res Biol. 2018;16(1):28–35.
    5. Kikuchi A, Kishida S, Yamamoto H. Regulation of Wnt signaling by protein-protein interaction and post-translational modifications. Exp Mol Med. 2006;38(1):1.
    6. Giles RH, van Es JH, Clevers H. Caughtup in a Wnt storm: Wnt signalling in cancer. Biochim Biophys Acta 2003;1653:1-24.
    7. Dolled-Filhart M, McCabe A, Giltnane J, Creggar M, Camp RL. Quantitative in situ analysis of beta catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006;66(10):5487-94.
    8. MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9-26.
    9. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestrogens, normal breast cell proliferation and breast cancer.
    10. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409–14.
    11. Clelia M, Antonio M, Giovanni M. Metabolic changes in cancer patients. Current Medicinal Chemistry 2011;4(10):281-5.
    12. Brennan KR, Brown AM. Wnt family proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004; 9: 119-31.
    13. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23:4215–24.
    14. Zeng YA, Nusse R. Wnt proteins are self renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell. 2010;6:568–77.
    15. Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA,Sutherland RL,O’Toole SA.Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2010;19:301–9.














    1. Perou CM, Sorlie T, Eisen MB, Matt VR, Jeffrey SS, Rees CA, et al. Molecular portrait of human breast tumours. Nature 2000;406:747-52.
    2. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA2008; 299 (2): 194–201.
    3. Smith CJ, Ryckman KK. Epigenetic and developmental influences on the risk of obesity, diabetes, and metabolic syndrome. Diabetes Metab Syndr Obes. 2015;8:295–302.
    4. Erdogan IZ, et al. Preoperative lymphedema-related risk factors in early-stage breast cancer. Lymphat Res Biol. 2018;16(1):28–35.
    5. Kikuchi A, Kishida S, Yamamoto H. Regulation of Wnt signaling by protein-protein interaction and post-translational modifications. Exp Mol Med. 2006;38(1):1.
    6. Giles RH, van Es JH, Clevers H. Caughtup in a Wnt storm: Wnt signalling in cancer. Biochim Biophys Acta 2003;1653:1-24.
    7. Dolled-Filhart M, McCabe A, Giltnane J, Creggar M, Camp RL. Quantitative in situ analysis of beta catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006;66(10):5487-94.
    8. MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9-26.
    9. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestrogens, normal breast cell proliferation and breast cancer.
    10. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409–14.
    11. Clelia M, Antonio M, Giovanni M. Metabolic changes in cancer patients. Current Medicinal Chemistry 2011;4(10):281-5.
    12. Brennan KR, Brown AM. Wnt family proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004; 9: 119-31.
    13. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23:4215–24.
    14. Zeng YA, Nusse R. Wnt proteins are self renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell. 2010;6:568–77.
    15. Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA,Sutherland RL,O’Toole SA.Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2010;19:301–9.
















    1. Perou CM, Sorlie T, Eisen MB, Matt VR, Jeffrey SS, Rees CA, et al. Molecular portrait of human breast tumours. Nature 2000;406:747-52.
    2. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA2008; 299 (2): 194–201.
    3. Smith CJ, Ryckman KK. Epigenetic and developmental influences on the risk of obesity, diabetes, and metabolic syndrome. Diabetes Metab Syndr Obes. 2015;8:295–302.
    4. Erdogan IZ, et al. Preoperative lymphedema-related risk factors in early-stage breast cancer. Lymphat Res Biol. 2018;16(1):28–35.
    5. Kikuchi A, Kishida S, Yamamoto H. Regulation of Wnt signaling by protein-protein interaction and post-translational modifications. Exp Mol Med. 2006;38(1):1.
    6. Giles RH, van Es JH, Clevers H. Caughtup in a Wnt storm: Wnt signalling in cancer. Biochim Biophys Acta 2003;1653:1-24.
    7. Dolled-Filhart M, McCabe A, Giltnane J, Creggar M, Camp RL. Quantitative in situ analysis of beta catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006;66(10):5487-94.
    8. MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9-26.
    9. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestrogens, normal breast cell proliferation and breast cancer.
    10. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409–14.
    11. Clelia M, Antonio M, Giovanni M. Metabolic changes in cancer patients. Current Medicinal Chemistry 2011;4(10):281-5.
    12. Brennan KR, Brown AM. Wnt family proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004; 9: 119-31.
    13. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23:4215–24.
    14. Zeng YA, Nusse R. Wnt proteins are self renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell. 2010;6:568–77.
    15. Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA,Sutherland RL,O’Toole SA.Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2010;19:301–9.














    1. Perou CM, Sorlie T, Eisen MB, Matt VR, Jeffrey SS, Rees CA, et al. Molecular portrait of human breast tumours. Nature 2000;406:747-52.
    2. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA2008; 299 (2): 194–201.
    3. Smith CJ, Ryckman KK. Epigenetic and developmental influences on the risk of obesity, diabetes, and metabolic syndrome. Diabetes Metab Syndr Obes. 2015;8:295–302.
    4. Erdogan IZ, et al. Preoperative lymphedema-related risk factors in early-stage breast cancer. Lymphat Res Biol. 2018;16(1):28–35.
    5. Kikuchi A, Kishida S, Yamamoto H. Regulation of Wnt signaling by protein-protein interaction and post-translational modifications. Exp Mol Med. 2006;38(1):1.
    6. Giles RH, van Es JH, Clevers H. Caughtup in a Wnt storm: Wnt signalling in cancer. Biochim Biophys Acta 2003;1653:1-24.
    7. Dolled-Filhart M, McCabe A, Giltnane J, Creggar M, Camp RL. Quantitative in situ analysis of beta catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006;66(10):5487-94.
    8. MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9-26.
    9. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestrogens, normal breast cell proliferation and breast cancer.
    10. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature. 2003;423:409–14.
    11. Clelia M, Antonio M, Giovanni M. Metabolic changes in cancer patients. Current Medicinal Chemistry 2011;4(10):281-5.
    12. Brennan KR, Brown AM. Wnt family proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 2004; 9: 119-31.
    13. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23:4215–24.
    14. Zeng YA, Nusse R. Wnt proteins are self renewal factors for mammary stem cells and promote their long-term expansion in culture. Cell Stem Cell. 2010;6:568–77.
    15. Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA,Sutherland RL,O’Toole SA.Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2010;19:301–9.